---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-078373"
form_type: "8-K/A"
ticker: null
cik: "0001499785"
company_name: "Tengjun Biotechnology Corp."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:36:17.932744+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tengjun Biotechnology restates FY2022 financials; appoints interim CEO/CFO after death of prior officer

## Summary
- Board concludes FY2022 10-K financials should no longer be relied upon due to accounting methodology errors.
- Auditor PWN LLP discovered discrepancies during Q2 review; errors include accounting policies and estimates.
- Company to restate FY2022 financials; transition from manual to automated accounting system identified discrepancies.
- Caihong Qu appointed as director, interim CEO and CFO effective August 10, 2023, replacing Xianchang Ma (deceased).
- PWN LLP agrees with the company's statements in the Form 8-K/A filing.

## SEC filing metadata
- accession: 0001213900-23-078373
- form_type: 8-K/A
- cik: 0001499785
- company_name: Tengjun Biotechnology Corp.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1499785/000121390023078373/0001213900-23-078373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1499785/000121390023078373/ea185571-8ka2_tengjun.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-078373
- JSON: https://secwatch.observer/filing/0001213900-23-078373.json
- Plain text: https://secwatch.observer/filing/0001213900-23-078373.txt

## Key facts
- Auditor Changes
  Tengjun Biotechnology Corp. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: ear ended December 31, 2022, should no longer be relied upon due to accounting methodology errors in such financial statements and that the Board deems it advisable and in the best interests of the Company to restate the financial statements by amending its annual report
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023078373/0001213900-23-078373-index.htm
- Executive change
  Caihong Qu was appointed as Interim Chief Executive Officer and Chief Financial Officer and Director at Tengjun Biotechnology Corp..
  - Action: appointed
  - Role: Interim Chief Executive Officer and Chief Financial Officer and Director
  source text: On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023078373/0001213900-23-078373-index.htm
- Executive change
  Xianchang Ma departed as Director, Chief Executive Officer and Chief Financial Officer at Tengjun Biotechnology Corp..
  - Action: passed away
  - Role: Director, Chief Executive Officer and Chief Financial Officer
  source text: Ms. Qu is the late wife of Mr. Xianchang Ma, our previous Director, CEO and CFO, who passed away on August 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1499785/000121390023078373/0001213900-23-078373-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.